The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kuznetsova I.V.

Preservation of ovarian reserve in patients with endometriosis

Authors:

Kuznetsova I.V.

More about the authors

Journal: Russian Journal of Human Reproduction. 2016;22(4): 37‑42

DOI: 10.17116/repro201622437-42

Read: 9772 times

Download PDF (RU)
Contact the author
Table of contents

PRESERVATION OF OVARIAN RESERVE IN PATIENTS WITH ENDOMETRIOSIS
PRESERVATION OF OVARIAN RESERVE IN PATIENTS WITH ENDOMETRIOSIS

To cite this article:

Kuznetsova IV. Preservation of ovarian reserve in patients with endometriosis. Russian Journal of Human Reproduction. 2016;22(4):37‑42. (In Russ.)
https://doi.org/10.17116/repro201622437-42

Подписка 2025-2 (Russian Journal of Human Reproduction)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
The dile­mma of mana­gement of patients with endo­metrioma and infe­rtility. Russian Journal of Human Reproduction. 2024;(4):29-37
The place of GnRH anta­gonists in modern ART programs: the possibilities of using of new drug of gani­relix. Russian Journal of Human Reproduction. 2024;(4):38-50
An inte­grated approach to endo­metrial examination in case of repeated failures in ART cycles: a pilot study. Russian Journal of Human Reproduction. 2024;(4):51-58
The influence of embryo culture technologies using traditional and TLT incu­bators on reproductive outcomes in women with different prognoses for the success of in vitro fertilization. Russian Journal of Human Reproduction. 2024;(4):71-77
Pathogenetic aspe­cts of chro­nic pelvic pain in endo­metriosis: diagnostic prospects (literature review). Russian Journal of Human Reproduction. 2024;(4):112-120
The role of systemic and local immu­nity in the pathogenesis of endo­metriosis of varying degrees of prevalence of the process: a modern view. Russian Journal of Human Reproduction. 2024;(5):6-14
Dyna­mics of the condition of patients with premature ovarian insu­fficiency and the autoantibody profile before and after the use of new surgical technologies in complex treatment. Russian Journal of Human Reproduction. 2024;(5):25-34
Correlation depe­ndence of tissue inhi­bitor of meta­lloproteinase-1 levels and follicular fluid morphology in patients with combined (uterine myoma and endo­metriosis) infe­rtility in the ART-programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(4):21-28
Significance of cell therapy in treatment of patients with thin endo­metrium and Ashe­rman’s syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):42-48
Quality of life and psychosomatic status of women of reproductive age with adenomyosis. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):83-89

Endometriosis is mainly prevalent in women of mature reproductive age. It affects fertility negatively independently of chief complaints. Treatment of endometriosis may also decrease fertility, thus keeping relevant the goal of maintaining the ability to conceive. In the meantime, there are certain concerns that surgery or pharmacotherapy of endometriosis may decrease ovarian reserve, which is considered a marker of fertility. These concerns often impede the proper clinical decision. However, they are based on the incomplete knowledge about the very concept of ovarian reserve, the influence of endometriosis on ovarian function and drug action affecting ovarian steroidogenesis and folliculogenesis.

Keywords:

endometriosis
fertility
ovarian reserve
anti-mullerian hormone
infertility
gonadotropin-releasing hormone agonists

Authors:

Kuznetsova I.V.

List of references:

  1. Вroekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685-718.
  2. Loh JS, Maheshwari A. Anti-Mullerian hormone - is it a crystal ball for predicting ovarian ageing? Hum Reprod. 2011;26:2925-2932.
  3. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013;99:963-969.
  4. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction. 2006;131:1-9.
  5. Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol. 2010;150:166-170.
  6. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113-130.
  7. van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, Broekmans FJ. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010;25:221-227.
  8. Hadlow N, Longhurst K, McClements A, Natalwala J, Brown SJ, Matson PL. Variation in antimullerian hormone concentration during the menstrual cycle may change the clinical classification of the ovarian response. Fertil Steril. 2013;99:1791-1797.
  9. Steiner AZ. Clinical implications of ovarian reserve testing. Obstet Gynecol Surv. 2009;64:120-128.
  10. Robertson DM, Hale GE, Fraser IS, Hughes CL, Burger HG. A proposed classification system for menstrual cycles in the menopause transition based on changes in serum hormone profiles. Menopause. 2008;15:1139-1144.
  11. 11.`Sowers MR, McConnell D, Gast K, et al. Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril. 2010;94:1482-1486.
  12. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93:3478-3483.
  13. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One. 2011;6:e22024.
  14. Somigliana E, Vercellini P, Vigano P, Ragni G, Crosignani PG. Should endometriomas be treated before IVF-ICSI cycles? Hum Reprod Update. 2006;12:57-64.
  15. Lemos NA, Arbo E, Scalco R, Weiler E, Rosa V, Cunha-Filho JS. Decreased anti-Mullerian hormone and altered ovarian follicular cohort in infertile patients with mild/minimal endometriosis. Fertil Steril. 2008;89:1064-1068.
  16. Kim JY, Jee BC, Suh CS, Kim SH. Preoperative serum anti-mullerian hormone level in women with ovarian endometrioma and mature cystic teratoma. Yonsei Med J. 2013;54:921-926.
  17. Pacchiarotti A, Frati P, Milazzo GN, Catalano A, Gentile V, Moscarini M. Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis. Eur J Obstet Gynecol Reprod Biol. 2014;172:62-64.
  18. Uncu G, Kasapoglu I, Ozerkan K, Seyhan A, Oral Yilmaztepe A, Ata B. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve. Hum Reprod. 2013;28:2140-2145.
  19. Streuli I, de Ziegler D, Gayet V, Santulli P, Bijaoui G, de Mouzon J, Chapron C. In women with endometriosis anti-Mullerian hormone levels are decreased only in those with previous endometrioma surgery.
Hum Reprod. 2012;27:3294-3303.
  20. Kitajima M, Defrere S, Dolmans MM, Colette S, Squifflet J, Van Langendonckt A, Donnez J. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011;96:685-691.
  21. Schubert B, Canis M, Darcha C, Artonne C, Pouly JL, Dechelotte P, Boucher D, Grizard G. Human ovarian tissue from cortex surrounding benign cysts: a model to study ovarian tissue cryopreservation. Hum Reprod. 2005;20:1786-1792.
  22. Kitajima M, Khan KN, Hiraki K, Inoue T, Fujishita A, Masuzaki H. Changes in serum anti-Müllerian hormone levels may predict damage to residual normal ovarian tissue after laparoscopic surgery for women with ovarian endometrioma. Fertil Steril. 2011;95(8):2589-2591.
  23. Chang HJ, Han SH, Lee JR, Jee BC, Lee BI, Suh CS, Kim SH. Impact of laparoscopic cystectomy on ovarian reserve: serial changes of serum anti-Mullerian hormone levels. Fertil Steril. 2010;94:343-349.
  24. Iwase A, Hirokawa W, Goto M, Takikawa S, Nagatomo Y, Nakahara T, Manabe S, Kikkawa F. Serum anti-Mullerian hormone level is a useful marker for evaluating the impact of laparoscopic cystectomy on ovarian reserve. Fertil Steril. 2010;94:2846-2849.
  25. Ercan CM, Duru NK, Karasahin KE, Coksuer H, Dede M, Baser I. 
Ultrasonographic evaluation and anti-mullerian hormone levels after laparoscopic stripping of unilateral endometriomas. Eur J Obstet Gynecol Reprod Biol. 2011;158:280-284.
  26. Ercan CM, Sakinci M, Duru NK, Alanbay I, Karasahin KE, Baser I. Antimullerian hormone levels after laparoscopic endometrioma stripping surgery. Gynecol Endocrinol. 2010;26:468-472.
  27. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2012;97:3146-3154.
  28. Somigliana E, Berlanda N, Benaglia L, Vigano P, Vercellini P, Fedele L. 
Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimullerian hormone level modifications. Fertil Steril. 2012;98:1531-1538.
  29. Hirokawa W, Iwase A, Goto M, Takikawa S, Nagatomo Y, Nakahara T, Bayasula B, Nakamura T, Manabe S, Kikkawa F. The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. Hum Reprod. 2011;26:904-910.
  30. Sugita A, Iwase A, Goto M, Nakahara T, Nakamura T, Kondo M, Osuka S, Mori M, Saito A, Kikkawa F: One-year follow-up of serum antimullerian hormone levels in patients with cystectomy: are different sequential changes due to different mechanisms causing damage to the ovarian reserve? Fertil Steril. 2013;100(2):513-522.
  31. Alborzi S, Keramati P, Younesi M, Samsami A, Dadras N. The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas. Fertil Steril. 2014;101:427-434.
  32. Tsolakidis D, Pados G, Vavilis D, Athanatos D, Tsalikis T, Giannakou A, Tarlatzis BC. The impact on ovarian reserve after laparoscopic ovarian cystectomy versus three-stage management in patients with endometriomas: a prospective randomized study. Fertil Steril. 2010;94:71-77.
  33. Ferrero S, Venturini PL, Gillott DJ, Remorgida V, Maggiore ULR. Hemostasis by bipolar coagulation versus suture after surgical stripping of bilateral ovarian endometriomas: a randomized controlled trial. J Minim Invasive Gynecol. 2012;19:722-730.
  34. Sonmezer M, Taskin S, Gemici A, Kahraman K, Ozmen B, Berker B, Atabekoglu C. Can ovarian damage be reduced using hemostatic matrix during laparoscopic endometrioma surgery? A prospective, randomized study. Arch Gynecol Obstet. 2013;287:1251-1257.
  35. Zaitoun MM, El Behery MM. Comparing long term impact on ovarian reserve between laparoscopic ovarian cystectomy and open laprotomy for ovarian endometrioma. J Ovarian Res. 2013;6:76.
  36. Lee DY, Young Kim N, Jae Kim M, Yoon BK, Choi D. Effects of laparoscopic surgery on serum anti-Mullerian hormone levels in reproductive-aged women with endometrioma. Gynecol Endocrinol. 2011;27:733-736.
  37. Celik HG, Dogan E, Okyay E, Ulukus C, Saatli B, Uysal S, Koyuncuoglu M. Effect of laparoscopic excision of endometriomas on ovarian reserve: serial changes in the serum antimullerian hormone levels. Fertil Steril. 2012;97:1472-1478.
  38. Urman B, Alper E, Yakin K, Oktem O, Aksoy S, Alatas C, Mercan R, Ata B. Removal of unilateral endometriomas is associated with immediate and sustained reduction in ovarian reserve. Reprod Biomed Online. 2013;27:212-216.
  39. Iwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F. Anti-Mullerian Hormone and Assessment of Ovarian Reserve After Ovarian Toxic Treatment: A Systematic Narrative Review. Reprod Sci. 2015;22(5):519-526.
  40. Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009;63:280-291.
  41. Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF. Prediction of Postchemotherapy Ovarian Function Using Markers of Ovarian Reserve. Oncologist. 2014;19(1):68-74.
  42. Partridge AH, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007;43(11):1646-1653.
  43. Su HI, Haunschild C, Chung K, Komrokian S, Boles S, Sammel MD, De Michele A. Pre-chemotherapy anti-mullerian hormone, age and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014;120(23):3691-3698.
  44. Gerber B, Dieterich M, Müller H, Reimer T. Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res Treat. 2008;108(1):1-7.
  45. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045-1051.
  46. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol. 2008;26(5):753-758.
  47. Bodai BI, Tuso Ph. Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. Perm J. 2015;19(2):48-79.
  48. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917-2931.
  49. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117:561-567.
  50. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91:694-697.
  51. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril. 2008;89:166-173.
  52. Behringer K, Wildt L, Mueller H, et al. Final results of a phase II trial from the German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated withc escalated BEACOPP for advanced-stage Hodgkin lymphoma. Ann Oncol. 2010;21(10):2051-2060.
  53. Somers EC, Christman GM, Fisseha S, Marder W, McCune WJ. Response to "Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist. 2008;13:613-614.
  54. Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update. 2008;14:553-561.
  55. Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a metaanalysis. J Womens Health (Larchmt). 2009;18:311-319.
  56. Shen Y-W, Zhang X-M, Lv M, Chen L, et al. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and metaanalysis. Onco Targets Ther. 2015;8:3349-3359.
  57. Marder W, McCune WJ, Wang L, Wing JJ, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in pre-menopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-627.
  58. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306:269-276.
  59. Su HI, Maas K, Sluss PM, Chang RJ, Hall JE, Joffe H. The Impact of Depot GnRH Agonist on AMH Levels in Healthy Reproductive-Aged Women. J Clin Endocrinol Metab. 2013;98(12):E1961-E1966.
  60. Hong IS, Klausen C, Cheung AP, Leung PC. Gonadotropin-releasing hormone-I or II interacts with IGF-I/Akt but not connexin 43 in human granulosa cell apoptosis. J Clin Endocrin Metab. 2012;97(2):525-534.
  61. Nigrinakis K, Bersinger NA, McKinnon B, et al. Regression of the inflamattory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):550-554.
  62. Muramatsu T. Structure and function of midkine as a basis of its pharmacological effects. Br J Pharmacol. 2014;171(4):814-826.
  63. Osuga Y. Novel therapeutic strategies for endometriosis: a pathophysiological perspective. Gynecol Obstet Invest. 2008;66(Suppl 1):3-9.
  64. Huang F, Wang H, Zou Y, Liu Q, Cao J, Yin. Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients with endometriosis in vitro. Int J Clin Exp Pathol. 2013;6(11):2487-2496.
  65. Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400-412.
  66. Yang XH, Ji F, AiLi A, TuerXun H, He Y, Ding Y. Effects of laparoscopic ovarian endometriosis cystectomy combined with postoperative GnRH-α therapy on ovarian reserve, pregnancy and outcome recurrence. Clin Exp Obstet Gynecol. 2014;41(3):272-275.
  67. Picard-Hagen N, Lhermie G, Florentin S, Merle D, Frein P, Gayrard V. Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle. Theriogenology. 2015;84(2):177-183.
  68. Siristatidis CS, Gibreel A, Basios G, Maheshwari A, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev. 2015;11:CD006919.
  69. Brown J, Farquhar C. An overview of treatments for endometriosis. JAMA. 2015;313(3):296-297.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.